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ABSTRACT
Velcade is one of the inescapable drug to treat patient suffering from multiple 
myeloma (MM) and resistance to this drug represents a major drawback for patients. 
However, the mechanisms underlying velcade resistance remain incompletely 
understood. We derived several U266 MM cell clones that resist to velcade. U266-
resistant cells were resistant to velcade-induced cell death but exhibited a similar 
sensitivity to various proapoptotic stimuli. Careful analysis of proteosomal subunits 
and proteasome enzymatic activities showed that neither the composition nor the 
activity of the proteasome was affected in velcade-resistant cells. Elimination of 
velcade-induced poly-ubiquitinated proteins and protein aggregates was drastically 
stimulated in the resistant cells and correlated with increased cell survival. Inhibition 
of the lysosomal activity in velcade-resistant cells resulted in an increase of cell 
aggregates and decrease survival, indicating that aggregates are eliminated through 
lysosomal degradation. In addition, pangenomic profiling of velcade-sensitive and 
resistant cells showed that the small heat shock protein HSPB8 was overexpressed in 
resistant cells. Finally, gain and loss of function experiment demonstrated that HSPB8 
is a key factor for velcade resistance. In conclusion, HSPB8 plays an important role 
for the elimination of aggregates in velcade-resistant cells that contributes to their 
enhanced survival.
INTRODUCTION
The ubiquitin-proteasome pathway plays an essential 
role in the degradation of 80% of ubiquitin-tagged 
intracellular proteins, many of which play a regulatory 
role in cell proliferation, cell survival, and signaling 
processes [1-3]. Degradation of regulatory proteins by 
this process is essential for maintaining normal cellular 
function. In cancer cells, proteasome is also required for 
the tumor cell growth, angiogenesis and apoptosis [4]. 
Proteasome inhibition has emerged as a new therapeutic 
option against cancer [5]. Bortezomib (PS341, velcade) 
is the first proteasome inhibitor that has been approved 
for the treatment of multiple myeloma (MM), resulting Oncotarget 6253 www.impactjournals.com/oncotarget
in outstanding response rate in both relapsed/refractory 
and newly diagnosed MM patients [6, 7]. Velcade is a 
reversible inhibitor that target primarily the β5-subunit 
(PSMB5) subunit/chymotrypsin-like proteolytic activity of 
the 26S proteasome and to a lesser extend the β1 (PSMB6) 
subunit/caspase-like activity. At higher concentrations, 
velcade also inhibits the trypsin-like activity harbored by 
the β2 (PSMB7) proteasome subunit [8]. Velcade disrupts 
the equilibrium between protein biosynthesis and protein 
degradation, which results in cell death by apoptosis. 
Proteasome inhibition leads to the accumulation of 
damaged proteins in the intracellular environment which 
causes endoplasmic reticulum overload integrated as an 
ER stress [9]. Then the cell induces protective responses, 
so called the unfolded protein response (UPR) that 
promotes refolding or elimination of damaged proteins. 
If the accumulation of damaged proteins is excessive, cell 
can at last triggers apoptosis through CHOP, caspase-4 and 
caspase-12 activation. It was also reported that proteasome 
inhibition triggers apoptosis by affecting the levels of 
many regulatory proteins, resulting in inhibition of nuclear 
factor κB (NF-κB), increased activity P53 and Bax leading 
to the activation of c-Jun NH2 –terminal kinase (JNK), 
which in turn activates caspase-8 and caspase-3 [10]. 
Multiple myeloma (MM) is a plasma cell 
malignancy [11] that remains incurable despite 
conventional treatment [12] or high-dose therapy [13]. It 
has a prevalence of 50 000 patients in the United States, 
occurring in approximately 16 000 new individuals each 
year. Autologous stem cell transplantation remains a good 
option for treating this disease; however, all patients will 
unavoidably relapse. Therefore, considerable efforts have 
been devoted to the development of new therapeutic 
strategies for the treatment of patients suffering from 
MM. Drugs such as lenalidomide (Revlimid®) and 
bortezomib (Velcade®) have significantly improved the 
overall survival rates of patients [14]. Despite promising 
clinical activity, some patients with MM failed to respond 
to velcade therapy or respond briefly and relapse [15]. 
The mechanism of velcade resistance remains puzzling. 
In lymphoma cells, high constitutive expression of 
heat shock protein 27 (HSP27) was reported to confer 
resistance to velcade [16]. In the context of acquired 
resistance to velcade, two previous studies reported 
an  enhanced  cellular  efflux  via  the  overexpression  of 
multidrug resistance (MDR) transporter P-glycoprotein 
(Pgp; ABCB1; MDR1) [17] or multidrug resistance-
related protein 1 (MRP1;ABCC1) [18] in ovarian cells. 
To date, different individual cell lines (including MM cell 
lines) have been adapted to increased concentrations of 
velcade [19-24]. In most of these studies, mutations in the 
active center of the β5 polypeptide have been repeatedly 
reported (G322A, C323T, C326T), that either lead or 
not to increased chymotryptic activity with or without 
overexpression of individual proteasome subunits.
In the present study, we derived several U266 
MM cell clones that resist to velcade. U266-resistant 
cell clones were fully resistant to velcade-induced cell 
death compared to their sensitive parental counterpart 
but exhibited a similar sensitivity to a large spectrum 
of  proapoptotic  stimuli.  Neither  the  composition  nor 
the activity of the proteasome was affected in velcade-
resistant cells. Importantly, elimination of velcade-induced 
poly-ubiquinated proteins and protein aggregates was 
drastically stimulated in resistant cells and correlated with 
an increase in cell survival in the presence of the drug. 
Inhibition of the lysosomal activity in velcade-resistant 
cells resulted in a diminution of cell aggregates and 
increased survival, indicating that protein aggregates are 
eliminated through lysosomal degradation. In addition, 
pangenomic profiling of velcade-sensitive and resistant 
cell lines showed that the small heat shock protein HSPB8 
was overexpressed in resistant cells. Finally, gain and loss 
of function experiment demonstrated that HSPB8 is a key 
factor for velcade resistance. In conclusion, these findings 
establish for the first time that HSPB8 plays an important 
role for the elimination of cell aggregates in velcade-
resistant cells that contributes to their enhanced survival.
RESULTS
Generation and characterization of multiple 
myeloma cell lines resistant to velcade
To gain insights into the molecular mechanisms of 
resistance to conventional therapies in MM, we generated 
U266 cell clones resistant to velcade, one of the leading 
drug  to  treat  patients  suffering  from  MM.  For  that 
purpose, the U266 cell line was incubated with iterative 
and increasing concentrations of velcade for a long 
period of time. After 10 months of selection we generated 
a bulk of U266 cells that resist up 20 nM velcade. In a 
first set of experiments, we determined the sensitivity 
of these cells to velcade using the XTT cell metabolism 
assay. Supplementary Figure 1A showed the loss of cell 
metabolism induced by increasing concentrations of 
velcade on the bulk of U266 cells rendered resistant to 
10, 12.5, 15 or 20 nM of this proteasome inhibitor. In the 
control cells, the IC50 value for velcade was around 2 
nM, whereas 10-20 nM of the drug was required to inhibit 
50% of cell metabolism in the bulk of U266 cells. After 
serial dilutions, we obtained several U266 cell clones 
from the bulk of cells resistant to 20 nM velcade. In the 
U266 sensitive cell clones, the IC50 value for the velcade-
induced loss of cell metabolism was 4-5 nM compared to 
25-30 nM in the bulk of U266 resistant cells and clone 
U266R9 (Supplementary Figure 1B). Two clones namely, 
U266R6 and U266R11 were found to be highly resistant to 
velcade, with IC50 values of 80 and 100 nM, respectively. 
For  all  the  forthcoming  experiments  we  thus Oncotarget 6254 www.impactjournals.com/oncotarget
decided to use the U266R6 clone (R6) that exhibited 
an intermediary resistance (Supplementary Figure 1B). 
Resistance of the R6 cells to increasing doses of velcade 
after 24 or 48 h of treatment was further confirmed by the 
loss of cell metabolism induced by velcade (Figure 1A). 
Whatever the incubation time, there was a twenty fold 
increase in the concentration of velcade needed to induce 
a 50% loss of cell metabolism in R6 cells compared to 
their U266 counterparts (Figure 1A). There was also an 
excellent correlation between the loss of cell metabolism 
in U266 and R6 cells and velcade-mediated cell death 
assessed by the propidium iodide staining at 48 h (Figure 
1B) or the increase in caspase-3 specific enzymatic activity 
at 24 h (Figure 1C). Accordingly, caspase-3 activation and 
Poly-ADR Ribose Polymerase (PARP) cleavage were also 
visualized after 24 h or 48 h of velcade treatment in U266 
parental cells, but only poorly detected in their velcade-
resistant counterpart (Figure 1D).
U266 and R6 cells are sensitive to various 
proapoptotic stimuli but resistant to different 
proteasome inhibitors
We next investigated the effect of various 
proapoptotic stimuli on U266 and R6 cells. To this purpose 
both cell lines were treated with increasing concentrations 
of either staurosporine or melphalan, an alkylating agent 
routinely used for the treatment of MM for 24 h. The same 
cell lines were also incubated with various concentrations 
of thapsigargin and tunicamycin, two reticulum stress 
inducing agents or etoposide for 48h, because we 
established in preliminary experiments that a longer time 
of treatment with these three later drugs was necessary to 
induce a significant loss of cell metabolism in velcade-
treated cells. As expected, R6 cells exhibited a strong 
resistance to high concentrations of velcade (Figure 2A). 
Of note, U266 and R6 cells showed the same sensitivity 
to all the proapoptotic stimuli used, including melphalan 
(Figure 2B to F). Therefore, we concluded that R6 cells 
exhibited a selective resistance to velcade but not to other 
proapoptotic stimuli. 
To investigate whether R6 cells could exhibit a 
general resistance to proteasome inhibitors, we next 
look for the effect of clasto-lactacystin, adamanthane 
(proteosomal  β  subunit  inhibitor),  MG132  and 
epoxomycin in comparison with the effect of velcade. 
As shown on supplementary Figure 2, besides velcade, 
R6 cells were also highly resistant to clasto-lacatcystin 
and MG132 and to a lesser extent to adamanthane and 
epoxomycin, suggesting a global resistance to a large 
panel of proteasome inhibitors.
Figure 1: Characterization of a MM cell line resistant 
to velcade. A, U266 and R6 MM cell lines were incubated 
with increasing concentrations of velcade (1 to 100 nM) for 24 h 
(left panel) or 48 h (right panel). Then, the cells were collected 
and cell viability was assessed with the XTT cell metabolism 
assay. B, U266 and R6 cells were incubated with increasing 
concentrations of velcade (1 to 100 nM) for 48 h (left panel) or 
72 h (right panel). Then, the cells were harvested and incubated 
with Propidium iodide (PI), and the percentage of dead cells 
was assessed by flow cytometry. C, U266 and R6 cells were 
incubated with increasing concentrations of velcade (1 to 100 
nM) for 24 h. Then, the cells were collected and lysed in caspase 
buffer, and caspase activity was assessed using DEVD-AFC as 
substrate. D, U266 and and R6 cell lines were incubated with 
velcade (10 nM) for 1 h to 48 h. Then, the cells were collected, 
washed and lysed, and total protein extracts were subjected to 
SDS-PAGE immunoblot using anti-Parp, anti-Caspase-3 and 
anti-P42/44 antibodies.
Figure 2: U266 and R6 MM cells are equally sensitive 
to pro-apoptotic stimuli. A to F, U266 and R6 cells were 
incubated with either velcade (1 to 100 nM), staurosporin (10 
nM to 1 µm), etoposide (1 to 100 µM), melphalan (1 to 100 µM), 
thapsigargin (0.1 to 3 µM) or tunicamycin (0.1 to 3 µM) for the 
indicated times. Then, the cells were collected, and cell viability 
was assessed using the XTT cell metabolism assay. Oncotarget 6255 www.impactjournals.com/oncotarget
U266 and R6 cells exhibit the same proteasomal 
enzymatic activity 
The proteasome consists on three main enzymatic 
activities including pseudo-caspase-like / glutamyl 
transferase, chymotrypsin-like and trypsin-like 
proteolytic activities that can be assessed using the 
synthetic  fluorescent  substrates,  Z-Leu-leu-Glu-AMC, 
Suc-Leu-Leu-Val-Tyr-AMC  and  Ac-Arg-Leu-Arg-
AMC, respectively (Figure 3A). As illustrated on Figure 
3B, the global activity (i.e in the absence of velcade) 
of the proteasome was identical in U266 and R6 cells. 
The caspase-like and chymotrypsin-like activities were 
found to be similarly sensitive to velcade and to their 
specific proteasome inhibitors (MG132 and epoxomycin 
for the caspase-like and chymotrypsin-like activities, 
respectively)  (Figure  3B  left  and  middle  panel).  The 
tryspin-like activity in both cell lines was insensitive to 
velcade but sensitive to Tlck, an inhibitor of trypsin-like 
activities (Figure 3B right panel). Finally, we investigated 
whether small difference in sensitivity to velcade of 
the different proteolytic activities constitutive of the 
proteasome could contribute to the resistance of R6 cells 
to this drug. The dose-response curves for the inhibition 
by velcade of the caspase-like and chymotrypsin-like 
activities were superposable in U266 and R6 cells (Figure 
3C left and middle panels). In addition, as previously 
reported, velcade failed to inhibit tryspsin-like activity of 
the proteasome, (Figure 3C, right panel). In conclusion, 
our findings clearly demonstrate that the intrinsic activity 
of the proteasome is identical in U266 and R6 cells. 
Accordingly, expression of the different protease subunits 
of the proteasome (PSMB5, PSMB6 and PSMB7) was 
found to be similar in both cell lines (supplementary 
Figure 3A). As point mutations in the PSMB5 protein 
has been previously identified in some velcade-resistant 
cells [19, 21, 22, 24], we looked for potential mutations in 
this proteasome subunit. We were unable to detect neither 
this particular mutation nor any other ones in the PSMB5 
subunit present in R6 cells (supplementary Figure 3B). 
Therefore, we conclude that the nature or the activity of 
the proteasome is unaffected in our velcade-resistant U266 
cell line. 
Figure 3: U266 and R6 MM cells exhibit the same global proteasome activity. A, Table indicates the sequences of the 
substrates used to measure the caspase-like and the chymotrypsin-like, and the trypsin-like activities of the proteasome. B, U266 and R6 
cells were incubated with either velcade (10 nM), MG132 (1 µM), Epoxomycin (100 nM) or Tlck (100 µM) for 24 h. Then, the cells were 
collected, washed and lysed, and proteasome activities were measured using the specific AMC conjugated substrates. C, U266 and R6 cells 
were collected, washed and lysed, and normalized protein extracts were incubated with increasing concentrations of velcade (1 to 300 nM) 
with either MG132 (1 µM), Epoxomycin (100 nM) or Tlck (100 µM) for 1 h. Then, the cell lysates were collected and the proteasome 
activities were measured using the specific AMC conjugated substrates.Oncotarget 6256 www.impactjournals.com/oncotarget
R6 cells have lower levels of poly-ubiquitinated 
proteins and aggregates
It has been reported previously that Bortezomib 
(velcade) induced protein aggregate accumulation into 
the cytoplasm of the RPMI-8226 MM cell line [25]. Thus, 
the total level of poly-ubiquitaned proteins was evaluated 
in U266 and R6 cells after 24 or 48 h treatment with 
increasing concentrations of velcade. For concentrations 
of velcade ranging from 3 to 10 nM, there was a strong 
inhibition of poly-ubiquitinated proteins in R6 cells. This 
was particularly evident in R6 cells treated for 48 h with 
velcade  (Figure  4A).  Reduction  of  poly-ubiquitinated 
proteins in R6 cells is correlated with a significant gain 
of cell metabolism after 24 or 48 h in the presence of 
velcade concentrations ranging from 3 to 30 nM (Figure 
4B).  Finally,  the  clearance  of  intracellular  aggregates 
was increased in R6 cells compared to their sensitive 
counterpart for the same range of velcade concentrations 
(Figure 4B). To support the hypothesis that the resistance 
of R6 cells was due to a higher capacity to eliminate 
intracellular aggregates, both U266 and R6 cells were 
stimulated with H202 that is reported to induce cell death 
and protein aggregates (Supplementary Figure 4). In U266 
cells, increasing concentration of H202 induced a loss of 
cell metabolism (left panel) that was associated with an 
accumulation of protein aggregates (right panel). In R6 
cells, the loss of cell metabolism was dampened and the 
clearance of protein aggregates was increased. All together 
our data strongly suggest that an increased clearance of 
intracellular aggregates allows R6 cells to resist to the 
effect of velcade.
Velcade increases the autophagic flux in resistant 
cells and inhibition of lysosomal activity 
overcomes resistance to velcade
Because inhibition of proteasome by velcade 
triggers the aggresome/autophagy pathway leading to 
the elimination of protein aggregates by lysosomes, 
we first analysed the induction of autophagy following 
velcade  stimulation  in  both  U266  clones.  The  LC3 
protein is commonly used as a marker of autophagy. 
Figure 4: Velcade-treated R6 clone exhibits decreased accumulation of poly-ubiquitinated protein and cellular 
aggregates. A, U266 and R6 cells were stimulated with increasing concentrations of velcade (3 to 100 nM) for 24 h (left panel) or 48 h 
(right panel). Then the cells were collected and lysed, and normalized protein extracts were subjected to SDS-PAGE and immunoblotting 
using anti-polyubiquitin and anti-Tubulin antibodies. B, U266 and R6 cells were incubated with increasing concentrations of velcade (3 
to 100 nM) for 24 h (upper panels) or 48 h (lower panels). Then, the cells were collected and cell viability was assessed by the XTT cell 
metabolism assay (left panels). In parallel, the percentage of cells with aggregates was determined by flow cytometry (right panels).Oncotarget 6257 www.impactjournals.com/oncotarget
After proteolytic processing by Atg4, LC3 conjugaison 
with phosphatidylethanolamine allows its insertion into 
the autophagic vesicule membranes, thus promoting 
autophagy. The abundance of processed LC3 (LC3-II) 
serves as a surrogate indicator of autophagic activity. 
As  expected,  we  observed  a  slight  increase  of  LC3 
processing in both U266 and R6 cells treated with 
increasing doses of velcade that was nevertheless more 
robust in the R6 resistant clone (Figure 5A, upper panel). 
We next investigated whether the R6 cells exhibits an 
enhanced  autophagic  flux  by  using  the  combination 
of E64 and Pepstatin that inhibits lysosomal protease 
activities and consequently induces LC3-II accumulation. 
We observed an accumulation of LC3-II in both clones 
treated with E64 and Pepstatin indicating that the basal 
autophagic flux is similar in U266 and R6 cells. When 
proteasome and lysosome activities were inhibited by the 
combination of velcade and E64/Pepstatin respectively, 
LC3-II accumulation was maintained in the R6 resistant 
clone, whereas it was inhibited in the U266 parental 
clone.  Quantification  of  LC3II  processing  confirmed 
that when proteasomal and lysosomal activities were 
inhibited,  LC3-II  accumulation  was  dampened  in  the 
parental cell line, while it was maintained or ever slightly 
increased in the resistant clone (Figure 5A). We next 
analysed whether inhibition of lysosomal activity with 
the combination of E64 and pepstatin would affect cell 
viability and clearance of aggregates in U266 and R6 
cells treated with increasing doses of velcade. E64 + 
Pepstatin significantly increased the velcade-induced loss 
of cell metabolism and accumulation of cell aggregates 
in R6 cells after 24 h (Figure 5B and 5C). A similar 
loss of velcade-mediated cell metabolism and increase 
aggregate accumulation was observed in R6 cells treated 
with Chloroquine (10 µM), another inhibitor of lysosomal 
activity (Supplemental 5). R6 cells were also stimulated 
with increasing concentrations of MG132 in the presence 
or in absence of either Pep/E64 (Supplemental 6A) or 
Bafilomycin A1, another inhibitor of lysosomal activity 
(Supplemental 6B). Percentages of dead cells (upper 
panels) or cell metabolism assay (lower panels) showed 
that R6 cells were resistant to MG132 and that inhibition 
of the lysosomal activity resensitized R6 cells to MG132. 
Taken together, these data show that a better clearance of 
cellular aggregates by the aggresome/autophagy pathway 
upon velcade treatment is responsible for the increase 
in cell metabolism and the resistance of R6 cells to cell 
death.
Pangenomic profiling of U266 and R6 cells 
To gain insights into the mechanisms of resistance 
to velcade we next compared the transcriptome of U266 
parental population with both the R6 clone and the 
Figure 5: Inhibition of lysosomal degradation restores sensitivity to velcade in R6 cells. A, U266 and R6 cells were incubated 
with increasing concentrations of velcade (10 and 30 nM) in the presence or in absence of the combination of E64 and pepstatin (10 µM) 
for 24 h. Then, the cells were collected and lysed, and normalized protein extracts were subjected to SDS-PAGE and immunoblotting using 
anti-LC3 and anti-HSP60 antibodies. B and C, U266 and R6 cells were incubated with increasing concentrations of velcade (10 to 30 nM) 
in the presence or in absence of the combination of E64 and pepstatin (10 µM) for 24 h. Then, the cells were collected and cell viability was 
assessed by an XTT cell metabolism assay (B). In parallel, the percentage of cells with aggregates was determined by flow cytometry (C).Oncotarget 6258 www.impactjournals.com/oncotarget
initial bulk of resistant cells using whole genome human 
microarrays. Table S1 illustrated the 160 most down and 
up-regulated genes in the 2 resistant cell populations in 
basal conditions. Importantly, as shown on Figure 6A 
and 6B, we noticed a strong correlation between the 
distribution of log2 fold change between the 2 resistant 
cells, strongly suggesting that the gene profile found in 
the R6 clone is highly representative of velcade resistance. 
Among the genes modulated in R6 cells we focused on 
HSPB8, whose expression was increased 5-6 times in R6 
cells compared to their parental counterpart in microarray 
data (Figure 6C). Interestingly, this gene has been shown 
previously to be important for the clearance of aggregates. 
This protein functions as a chaperone in association with 
BAG3, a stimulator of macroautophagy, and favored 
degradation of unfolded poly-ubiquitinated protein 
through the lysosomal degradation pathway [26, 27]. 
HSPB8 is upregulated in velcade-resistant clones 
and is a key actor of resistance to this drug
Overexpression of the HSPB8 protein was 
confirmed in R6 cells by western blotting (Figure 7A). 
Importantly, HSP27 another heat shock protein was 
present at the same level in U266 and R6 cells (Figure 
7A). To disprove that increased expression of HSPB8 
could be a clonal particularity of the R6 cell line, we 
looked for its expression in the bulk of U266 resistant cells 
and in the different U266 cell clones. As shown on figure 
7B, we found a very good correlation between HSPB8 
expression in the different clones and their sensitivity to 
velcade (Figure 7B and supplementary Figure 1B). 
Next,  we  wanted  to  determine  whether  velcade 
can modulate HSPB8 expression level in U266 and R6 
clones.  In  accordance  with  the  pangenomic  profiling, 
RT-PCR experiment showed an increase in HSPB8 
mRNA in R6 cells but not U266 cells in basal conditions 
(Supplementary  Figure  7).  In  R6  cells,  increasing 
Figure 6: Whole genome profiling of velcade-resistant cells. RNA samples were prepared from U266 parental population or 
velcade-resistant cells (whole bulk and R6 clone) and mRNA profiles were determined with pan genomic arrays. A, Correlation between the 
Log2 Fold changes calculated between the 2 velcade-resistant cells and the parental population, as indicated. The determination coefficient 
(R²) was calculated using log2 fold changes from all microarrays probes. B, Heatmap comparing normalized log2 of the ratio between the 
2 velcade-resistant cells and the parental population, as indicated. Distance was measured using the Manhattan distance on the matrix of 
the log2 (ratio) and classification was performed using a complete agglomeration method. C, Normalized expression value of the HSPB8 
probe set in the 3 cell populations.Oncotarget 6259 www.impactjournals.com/oncotarget
concentrations of velcade led to a strong induction of 
HSPB8 mRNA, while the proteasome inhibitor induced 
a slight increase in HSPB8 mRNA expression at low dose 
of velcade in U266 cells (Supplementary Figure 7A). In 
R6 cells, induction of HSPB8 upon velcade treatment was 
also confirmed at the protein level (Supplementary Figure 
7B).
This prompted us to investigate further the role 
of HSPB8 in the resistance to velcade. To this aim, we 
performed gain and loss of function experiments in U266 
and R6 cells, respectively (Figure 7C and D). We first 
expressed myc-Tagged HSPB8 in U266 cells to a similar 
level than endogenous HSPB8 in R6 cells (Figure 7C 
upper panel). Increased expression of HSPB8 in R6 cells 
further reduced the very weak loss of cell metabolism 
induced by velcade. Importantly increased expression of 
HSPB8 in U266 cells significantly protects them from 
the velcade-induced loss of cell metabolism, whatever 
the concentrations of the drug used (Figure 7C middle 
panel). Indeed, transfected U266 cells that expressed the 
same level of HSPB8 than their R6 counterpart exhibited 
the same response to velcade. As expected, the resistance 
of U266 cells to velcade conferred by HSPB8 expression 
was correlated with a drastic diminution of cell aggregates 
Figure 7: HSPB8 overexpression in R6 cells is responsible for the resistance to velcade. A, U266 and R6 cells were collected, 
washed and lysed, and protein extracts were subjected to SDS-PAGE and immunoblotting using anti-HSPB8, anti-HSP27 and anti-HSP60 
antibodies. B, U266 and the various resistant clones obtained previously were subjected to SDS-PAGE and immunoblotting using anti-
HSPB8, anti-HSP27 and anti-HSP60 antibodies. C, U266 and R6 cells were transfected with either control PcDNA3-Myc or PcDNA3-
Myc-HSPB8 vectors. 48 h later, one fraction of the cells were harvested and lysed. Exogenous Myc-HSPB8 protein (upper band) and 
endogenous HSPB8 protein (lower band) level was quantified by western blotting using anti-HSPB8 antibody. Correct normalization of 
protein extracts was confirmed using anti-HSP60 antibody (upper panel). The second fraction of the cells was stimulated with increasing 
concentrations of velcade (5 to 20 nM) for 24 h. Then, the cells were collected and cell viability was assessed by the XTT cell metabolism 
assay (middle panel). In parallel, the percentage of cells with aggregates was determined by flow cytometry (lower panel). D, U266 and R6 
were transfected with either control siRNA or with HSPB8 siRNA. 48h later, one fraction of the cells was collected and lysed, and HSPB8 
protein silencing was confirmed by western blotting using anti-HSPB8 antibody. Normalization of protein extracts was confirmed using 
anti-HSP60 antibody (upper panel). The second portion of the cells was stimulated with increasing concentrations of velcade (5 to 20 nM) 
for 24 h. Cell viability was assessed using the XTT cell metabolism assay (middle panel). In parallel, the percentage of cells with aggregates 
was determined by flow cytometry (lower panel).Oncotarget 6260 www.impactjournals.com/oncotarget
(Figure 7C lower panel). 
To further confirm the implication of HSPB8 in the 
resistance to velcade, we knocked down its expression 
in U266 and R6 cells using a siRNA approach. Specific 
silencing  of  HSPB8  in  R6  cells  was  first  confirmed 
by Western Blotting (Figure 7D upper panel). HSPB8 
silencing failed to affect the velcade-mediated loss of cell 
metabolism in U266 cells conversely to cells treated with 
the control siLuc, indicating the lack of global toxicity 
of the HSPB8 siRNA. Importantly, HSPB8 knock down 
in R6 cells restored sensitivity to velcade whatever the 
concentrations used. At the higher concentrations of 
velcade, the loss of cell metabolism reached two third of 
the velcade effect in U266 cells (Figure 7D middle panel). 
Notably, resensitization of R6 cells to velcade was closely 
linked to a huge increase in cell aggregates (Figure 7D 
lower panel). Gain and loss of function experiments were 
also confirmed in the R11 resistant clone (Supplementary 
Figure 8). 
To  confirm  that  HSPB8  overexpression  inhibits 
specifically  the  proteasome  inhibitor-induced  loss 
of  cell  metabolism,  we  first  expressed  myc-Tagged 
HSPB8 in U266 and R6 cells and stimulated clones 
with either increasing concentrations of different 
proteasome inhibitors or with various proapoptotic 
stimuli (Supplemental Figure 9). As expected, in basal 
conditions, while R6 cells exhibited a strong resistance to 
the different proteasome inhibitors (panels A, B and C), 
U266 and R6 cells showed the same sensitivity to all the 
proapoptotic stimuli used (panels D, E and F). HSPB8 
overexpression in U266 cells dampened the proteasome 
inhibitor-induced loss of metabolism (panels A, B and C) 
while it had no effect on proapoptotic stimuli-induced loss 
of cell metabolism (panels D, E and F). Importantly, in R6 
cells, HSPB8 overexpression reduced slightly the loss of 
cell metabolism induced by proteasome inhibitors but had 
no effect on proapoptotic stimuli-induced cell metabolism. 
Overexpression of the myc-Tagged HSPB8 protein was 
confirmed  in  U266  and  R6  cells  by  western  blotting 
(panel G). Therefore, we concluded that overexpression 
of HSPB8 conferred a selective resistance to proteasome 
inhibitors but not to other proapoptotic stimuli.
Taken together our results highlight the key role of 
HSPB8 in the resistance to velcade that is in agreement 
with its capability to clear intracellular aggregates. 
DISCUSSION
The newly established velcade-resistant U266 MM 
cell lines described in the present report exhibited a strong 
cross-sensitivity to a wide panel of proteasome inhibitors 
but remained sensitive to various proapoptotic stimuli. 
These results indicate that R6 clones exhibit a selective 
resistance to proteasome inhibitors. In the context of 
acquired resistance to velcade, previous studies reported 
an  enhanced  cellular  efflux  via  the  overexpression  of 
multidrug resistance (MDR) transporter P-glycoprotein 
(Pgp) [17] or multidrug resistance-related protein 1 
(MRP1) [18]. We excluded this possibility because i) 
pangenomic profiling of velcade-sensitive and resistant 
cell lines didn’t highlight an overexpression of PgP 
transporter or MRP1 protein ii) parental U266 cells and the 
different resistant clones described herein were similarly 
sensitive to cell death inducers that act independently 
of the proteasome inhibition. Resistance to etoposide or 
thapsigargin was also reported to be linked to Pgp and 
MRP1 overexpression respectively [28, 29]. This is not 
the case in our velcade resistant cell lines in which are 
sensitive to both effectors.
To investigate the mechanisms of velcade resistance 
that occur frequently in hematopoietic malignancies, 
several studies were conducted in velcade adapted 
MM, myelomonocytic, promyelocytic, T lymphoblastic 
lymphoma/leukemia or Burkitt lymphoma cells cell lines 
[19-24, 30]. Authors reported mutations in the active 
center of the β5 polypeptide (PSMB5), which either lead 
or not to increased chymotryptic activity with or without 
overexpression of individual proteasome subunits. 
However, to the best of our knowledge, no evidence of 
mutations or overexpression of the PSMB5 proteasome 
subunit has been reported in any case of myeloma patient 
[31-34]. These results show that in myeloma patients 
resistant to velcade, the direct implication of a proteasome 
defect remains to be established. 
In our models velcade resistant U266 MM clones 
we failed to observe mutations or overexpression of 
the PSMB5 core leading to an increased chymotryptic 
activity. Moreover, no mutations or overexpression 
of the PSMB6 or PSMB7 proteasome subunits that 
could explain a reinforced caspase-like and trypsin-like 
activities, were detected (Supplemental 3 and data not 
shown). Using synthetic fluorescent substrates, we also 
measured the caspase-like, chymotrypsin-like and trypsin-
like proteolytic activities in either U266 or R6 cells or 
in the corresponding cell lysates incubated or not with 
velcade. We demonstrated that both U266 and R6 clones 
exhibited similar basal chymotrypsin-like and caspase-
like proteasome activities that were both sensitive to 
inhibition by velcade. In conclusion, our findings rule out 
the possibility that a modification in the intrinsic activity 
of the proteasome can explain the resistance of the R6 
clones to velcade. 
One mechanism that could explain the difference 
between our results and the one obtained from other 
groups could be the concentrations of velcade used to 
generate these U266 resistant clones. In the previous 
studies, the authors used concentrations of velcade up to 
1 µM to select their clones [19, 21, 22, 24]. In our case, 
we did not exceed 20 nM because this concentration 
corresponds to the dose commonly administered to 
patients (1.3 mg/m2) [35]. It is thus reasonable to assume 
that different resistance mechanisms are at play in the cells Oncotarget 6261 www.impactjournals.com/oncotarget
treated with low and high doses of velcade.
The aggresome/autophagy pathway is an important 
process that is critical for the degradation of a plethora 
of proteins via the lysosomes. This process is further 
involved when the proteasome/ubiquitin pathway is 
inhibited [36]. In our model, we observed accumulation 
of both poly-ubiquitinated and protein aggregates in 
both U266 and R6 cell lines stimulated with increased 
concentrations  of  velcade  (Figure  4).  These  results 
confirmed that both cell lines engaged a similar upstream 
molecular response following velcade challenging. 
Then, we showed that elimination of velcade-induced 
poly-ubiquitinated proteins and protein aggregates was 
drastically stimulated in resistant cells and correlated 
with an increased cell survival after 48 h in the presence 
of the drug. Inhibition of the lysosomal activity with the 
combination of E64 and Pepstatin (Figure 5B and C) or 
Chloroquine (Supplemental 5) in velcade-resistant cells 
resulted in an increase of cell aggregates and a decreased 
survival, indicating that protein aggregates are eliminated 
through the lysosomal pathway. Moreover, we showed 
that resistant cells engaged a more robust induction of 
autophagic flux upon velcade treatment compared to their 
parental counterpart (Figure 5A and B). These results are 
in agreement with findings from the literature reporting 
that i/ Proteasome inhibition by velcade resulted in the 
accumulation of ubiquitinated protein leading to protein 
aggregation and proteotoxicity [25] ii/ Inhibition of the 
proteasome by velcade triggers the aggresome/autophagy 
pathway leading to the elimination of protein aggregates 
by lysosomes [36, 37] and iii/ Inhibition of proteasome 
and aggresome functions induces a synergistic antitumor 
activity in MM [10, 38, 39]. To our knowledge and 
importantly, this is the first description of a MM model of 
velcade adapted-cells that reveals an enhance capacity to 
degrade toxic protein aggregates through the aggresome/
autophagy pathway.
To investigate further the mechanism of resistance 
to velcade, we next analyzed the alteration of gene 
expression in U266 and R6 cells using an Affymetrix 
pangenomic profiling. Heat Shock Proteins (HSP) have 
been extensively described to be implicated in protein 
quality control and the removal of misfolded proteins 
[40]. The main machinery involves molecular chaperones 
such as HSP70, HSP90 and small heat shock proteins (also 
called HSPB) which can recognize and bind unfolded 
proteins thereby preventing their aggregation. The fate of 
their bound substrates (renaturation or degradation by the 
aggresome/autophagy pathway) depends on the interaction 
of HSP70 with specific cochaperones such as the E3 ligase 
CHIP and the BAG domain containing proteins [41, 42]. 
We thus more specially focused on HSP protein family 
expression in velcade-sensitive and resistant clones. From 
the pangenomic study, we determined that among the 
HSP protein members, only the transcript encoding the 
Small Heath Shock Protein B8 (HSPB8, HSP22, H11, 
E2IG1) was overexpressed in R6 cells compared to their 
parental counterpart. Of note, gain and loss of function 
experiments demonstrated that HSPB8 is a key factor for 
velcade resistance in our cell line model. In association 
with BAG3 and HSP70, the chaperone activity of HSPB8 
was reported to be involved in the delivery of misfolded 
proteins to the macroautophagy machinery [26, 27]. 
Thus, the function of HSPB8 in velcade-resistant cells 
is in agreement with the increased autophagy flux and 
the exacerbated capacity to remove aggregates observed 
in R6 cells. Induction of BAG3, HSP70 and HSPB8 at 
both  the  RNA  and  protein  levels  was  reported  under 
stress conditions including proteasome inhibition [43, 
44] . In our model, we observed an induction of BAG3 
and HSP70 protein levels in both U266 parental and R6 
cells upon velcade treatment. HSPB8 protein induction 
was only observed in R6 clone treated with velcade (data 
not shown) reinforcing the importance of HSPB8 in the 
process of resistance to velcade. 
HSPB8 gene alteration and mutations have 
been reported in neurological disease. In this context, 
inactivating  HSPB8  mutations  (K141E,  K141N)  were 
described to cause distal motor neuropathy [45]. In 
contrast, overexpresion of HSPB8 was reported to 
prevent the aggregation of Htt43Q, a pathogenic form 
of Huntingtin responsible for Hungtington’s disease 
[46]. HSPB8 was also shown to promote autophagic 
removal of misfolded proteins involved in amyotrophic 
lateral sclerosis (ALS) [47]. Accumulation of aggresomes 
represents a novel mechanism by which to induce 
apoptosis, especially among cells where protein 
production and catabolism are critically important for 
malignant cell survival, as it is the case for malignant 
and normal immunoglobulin-producing plasma cells [37, 
48]. Thus, it is likely that in MM, HSPB8 up-regulation 
occurs as a plausible strategy for malignant plasmocytes 
to counteract the cytotoxic effect of velcade. The HSPB8 
protein level in patients suffering MM responding or 
relapsing to velcade treatment remains to be measured to 
verify this hypothesis. 
In conclusion, the results presented herein suggest 
that overexpression of HSPB8 in myeloma cells could play 
an important role for the elimination of cell aggregates in 




The U266 human MM cell line was purchased from 
the ATCC and were grown at 37°C under 5% CO2 RPMI 
medium (Gibco BRL, Paisley, UK) supplemented with 
10 % fetal calf serum (Gibco BRL, 10270), 50 units/ml Oncotarget 6262 www.impactjournals.com/oncotarget
penicillin, 50 mg/ml streptomycin (Lonza, DE17-602E) 
and 1 mM sodium pyruvate (Lonza, BE13-115E). 
Establishment of velcade resistant cell line 
From the parental U266 cell line, we established 
resistant clones by addition in the culture medium of 
increasing concentrations of velcade (up to 20 nM) for 
10 months. From the bulk corresponding to the final step 
of selection with velcade (20 nM), we isolated 12 clones 
by limiting dilution. For convenience, we focalized our 
study onto 3 representative clones (U266R6, U266R9 and 
U266R11). 
Reagents and antibodies 
Sodium  fluoride  (S7920),  sodium  orthovanadate 
(220590), phenylmethylsulfonyl fluoride (PMSF) (P7626), 
aprotinin (A162-B), leupeptin (SP-04-2217-B), Triton 
X-100 (N150), Earle’s Balanced Salt Solution (EBSS) 
(E3024), thapsigargin (T9033), tunicamycin (T7765), 
E64 (E3132), melphalan (M2011), and staurosporin 
(S4400) were purchased from Sigma. MG132 (BML-
PI102), Epoxomycin (BML-PI127) or Tlck (BML-PI121), 
Z-Leu-Leu-Glu-AMC  (BML-ZW9345),  Suc-Leu-Leu-
Val-Tyr-AMC (BML-P802) and Ac-Arg-Leu-Arg-AMC 
(BML-AW9785) were from Enzo Life Sciences. Pepstatin 
(EI-9-B) was obtained from Euromedex. Anti-Hsp60 (sc-
1722), anti-Ubiquitin (sc-8017), anti-Hsp27 (sc-1048) and 
anti-Hsp90 (sc-69703) were purchased from Santa Cruz 
Biotechnology. Anti-PSMB5 (PW8140), anti-PSMB6 
(PW8145) and anti-PSMB7 (PW8895) were from Enzo 
life sciences. Anti-PARP (9542), anti-HspB8 (30595), 
anti-LC3 (2775) and Hrp conjugated anti-rabbit (7074) 
antibodies were obtained from Cell Signaling Technology. 
Hrp-conjugated anti-mouse (P0260) and anti-goat (P0449) 
antibodies were from Dakopatts. Cleaved caspase 3 (9661) 
was purchased from Ozyme.
Immunoblotting 
After stimulation, the cells were lysed at 4°C in 
lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 20 
mM EDTA, 100 µM NaF, 10 µM Na3VO4, 1 mM PMSF, 
10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 % Triton 
X-100). The lysates were centrifuged at 16,000 ×g for 
15 min at 4°C, and the supernatants were supplemented 
with concentrated SDS sample buffer. A total of 30 µg 
of protein was separated on a 12 % polyacrylamide gel 
and transferred onto a PVDF membrane (Immobilon-P, 
Millipore, IPVH00010) in a 20 mM Tris, 150 mM glycine 
and 20 % ethanol buffer at 250 mA for 1 h 30 min at 4°C. 
After blocking the non-specific binding sites in saturation 
buffer (50 mM Tris pH 7.5, 50 mM NaCl, 0.15 % Tween, 
and 5 % BSA), the membranes were incubated with the 
specific antibodies, washed three times using TNA-1% 
NP-40 (50 mM Tris pH 7.5, and 150 mM NaCl) and 
incubated further with HRP-conjugated antibody for 1 h at 
room temperature. The immunoblots were revealed using 
the enhanced chemiluminescence detection kit (Pierce, 
32106). 
Knock down by siRNA 
Stealth small interfering RNAs (siRNA) targeting 
HSPB8 (HSS178150), were purchased from Invitrogen. 
Transfection of U266 cells was performed as described 
previously [49] using the Nucleofector system (Lonza, 
VCA-1003).  Briefly,  2.5  millions  of  cells  were 
electroporated with either control or HSPB8 siRNA (100 
nM) using nucleofector (kit C and program X-05). Then, 
the cells were plated in 5 ml of RPMI 10 % FCS media 
and incubated for 48 h at 37°C until experiment analysis.
HSPB8 transfection 
PcDNA-Myc-HSPB8 plasmid was kindly provided 
by Dr Jacques Landry (Centre of recherche cancerologie, 
University of Laval, Canada). Briefly, 3 millions of U266 
and R6 cells were electroporated with 2 µg of either 
PcDNA-Myc  or  PcDNA-Myc-HSPB8  vectors  using 
nucleofector (kit C Lonza, VCA-1003 and program X-05). 
Then, the cells were plated in 5 ml of RPMI 10 % FCS 
media and incubated for 48 h at 37°C until experiment 
analysis.
RNA preparation 
Total RNA were prepared from the U266 parental 
cell line, the R6 clone and the initial bulk of resistant cells 
using TRIzol reagent according to the manufacturer’s 
instructions (Invitrogen). Total RNA (1 µg) was reverse 
transcribed  into  cDNA  using  Superscript  II  reverse 
transcriptase (Invitrogen).
Microarrays experiment
Microarray analyses were performed on the 
GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa 
Clara, CA 95051, USA), according to the manufacturer’s 
instructions. RNA from each of the 3 cell population were 
labeled and hybridized. The experimental data will be 
deposited in the NCBI Gene Expression Omnibus (GEO) 
(http://  www.ncbi.nlm.nih.gov/geo/).  Normalization  of 
microarray data was performed using the Limma package 
available from Bioconductor (http://www.bioconductor.
org). using the RMA method and means of ratios from 
velcade-resistant cells versus U266 parental cells were Oncotarget 6263 www.impactjournals.com/oncotarget
calculated.
Measurement of cell metabolism (XTT) 
U266 cells or R6 clones were incubated in a 
96-well plate with the indicated concentrations of 
cell death inducers for 24 or 48 h. 50 µl of the XTT 
reagent (Roche Applied Science, 11-465-015) (sodium 
3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro) benzene sulfonic acid hydrate) was 
added to each well. The assay is based on the cleavage 
of the yellow tetrazolium salt XTT to form an orange 
formazan dye by metabolically active cells. The 
absorbance  of  the  formazan  product,  reflecting  cell 
viability, was measured at 490 nm. Each assay was 
performed in triplicate.
Cell Death assay 
Cell viability was measured using the propidium 
iodide (PI) dyed exclusion assay. Briefly, after treatment, 
the cells were collected and incubated with PI (10 µg/
ml) for 5 min. The percentage of PI positive cells was 
next analysed by flow cytometry using MACSQUANT 
Analyser (Myltenyi Biotech, 130-092).
Protein aggregates 
Measurement of protein aggregates was performed 
using the ProteoStat Aggresome Dectection Kit (ENZ-
51035-K100) from ENZO Life Sciences according to the 
manufacturer procedure. Briefly, after stimulation, cells 
were collected, washed with PBS and centrifugated (400 
×g for 5 min), and fixed with formaldehyde (4 %) for 30 
min at RT. Then, the cells were centrifugated (800 ×g for 
10 min), washed in PBS, and permeabilized (0.5 % Triton 
X-100, 3 mM EDTA, pH 8) for 30 min on ice. The cells 
were centrifugated again (800xg for 10 min), washed in 
PBS and incubated with the ProteoStat Aggresome Red 
Detection Reagent for 30 min at RT. Protein aggregates 
were measured by flow cytometry in the FL3 channel.
Measurement of Proteasome activity 
U266 and R6 cells were stimulated with velcade for 
24 h in the presence or the absence of MG132 (1 µM), 
Epoxomycin (100 nM) or Tlck (100 µM). Then, the cells 
were collected, washed, and lysed for 30 min at 4°C in a 
ATP-containing lysis buffer (50 mM HEPES pH 7.8, 5 
mM ATP, 0.5 mM DTT, 5 mM MgCl2 and 0.2 % Triton 
X-100). Cell lysates were cleared at 16,000 ×g for 15 
min at 4°C. Normalized protein lysates (10 µg/well) were 
incubated in a 96-well plate with 0.1 mM of either Z-Leu-
Leu-Glu-AMC, Suc-Leu-Leu-Val-Tyr-AMC or Ac-Arg-
Leu-Arg-AMC to measure caspase-like, chymotrypsin-
like and trypsin-like activities, respectively. Proteasome 
activities were measured by following emission at 460 nm 
(excitation at 390 nm). Each experiment was performed in 
quadruplicates and repeated at least four times.
Measurement of Proteasome activity in cell lysates 
U266 and R6 cells were collected and lysed, and 
normalized protein extracts (10 µg/well) were incubated 
in a 96-well plate with either velcade (10 nM), MG132 
(1 µM), Epoxomycin (100 nM) or Tlck (100 µM) for 3 h. 
Then, proteasome activities were measured as described 
above.
Caspase activity 
Following treatments, cells were lysed for 30 min at 
4°C in lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 
20 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/
ml aprotinin and 0.2 % Triton X-100), and lysates were 
cleared at 16,000 ×g for 15 min at 4°C. Each assay (in 
triplicate) was performed with 50 µg of protein prepared 
from control or stimulated cells. Briefly, cellular extracts 
were then incubated in a 96-well plate, with 0.2 mM of 
Ac-DEVD-AMC as substrates for various times at 37°C 
as previously described. Caspase activity was measured 
by following emission at 460 nm (excitation at 390 nm) in 
the presence or in absence of 10 µM of Ac-DEVD-CHO. 
Each experiment was performed in triplicates and repeated 
at least four times. 
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